相关临床试验
15
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
40.0%
尚未招募
3
20.0%
招募中
5
33.3%
终止
1
6.7%
暂无批准数据
- Australian researchers at RMIT University have developed experimental eyedrops using nano-cubosome technology to deliver lutein directly to the retina, potentially replacing painful eye injections for treating age-related macular degeneration and diabetic retinopathy. - The innovative delivery system uses cubosomes as tiny shields to protect lutein and release it in a controlled manner, successfully reaching retinal tissue in mouse studies and remaining stable at room temperature for months. - In laboratory tests, the lutein-loaded eyedrops reduced toxic compounds VEGF-A and IL-6 in retinal cells by activating the Nrf2/HO-1 antioxidant pathway, demonstrating potential therapeutic benefits. - While promising, the research remains in early stages with testing conducted only on healthy mice and cell cultures, requiring further animal studies and eventual human trials before clinical application.
- Melbourne-based Mirugen secured A$4.5 million in seed funding to develop its pioneering cell reprogramming technology targeting retinal diseases. - The company's lead program focuses on treating retinitis pigmentosa by reprogramming Muller glial cells to regenerate lost photoreceptors in the eye. - The therapy platform may also have applications for age-related macular degeneration and Stargardt disease, potentially addressing major causes of blindness worldwide. - Charlotte Casebourne Stock, who previously led Theolytics from inception to clinic, has been appointed as executive chair and acting CEO.
- Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams. - Notable appointments include former CDC Director Dr. Julie Louise Gerberding joining ARTIDIS and former Roche neuroscience head Dr. Paulo Fontoura taking on dual advisory roles. - Companies ranging from clinical-stage biotechs to established pharmaceutical firms are adding expertise in areas including oncology, neuroscience, infectious diseases, and antimicrobial resistance.
- A CRISPR-Cas13bt3 system, delivered via AAV, significantly reduced VEGFA mRNA and protein expression in human retinal organoids and VEGF-transgenic mouse models. - Single-cell RNA sequencing confirmed the system's high specificity, effectively reducing VEGFA in retinal pigment epithelium cells with minimal off-target effects. - Researchers found that multiplexed sgRNA delivery did not significantly enhance VEGFA knockdown efficiency compared to single sgRNA delivery. - The study, led by researchers from the Centre for Eye Research Australia and the University of Melbourne, highlights the potential of Cas13bt3 for targeted gene therapy in retinal diseases.
